Intervention

Tazemetostat

ClinicalTrials.gov intervention label

Clinical trials6
Recruiting1
Common conditions25
Lead sponsors shown4

Clinical trials

6 shown
A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate CancerNCT07407283 · 2026-04-08
RECRUITING
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPCNCT04846478 · 2021-06-28
ACTIVE_NOT_RECRUITING
A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate CancerNCT04179864 · 2019-11-18
TERMINATED
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)NCT03213665 · 2017-11-13
COMPLETED
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)NCT03155620 · 2017-07-31
ACTIVE_NOT_RECRUITING
Tazemetostat Expanded Access Program for Adults With Solid TumorsNCT03874455
NO_LONGER_AVAILABLE

Common conditions

Advanced Malignant Solid Neoplasm2Ann Arbor Stage III Non-Hodgkin Lymphoma2Ann Arbor Stage IV Non-Hodgkin Lymphoma2Metastatic Castration-resistant Prostate Cancer2Metastatic Prostate Cancer2Recurrent Ependymoma2Recurrent Ewing Sarcoma2Recurrent Glioma2Recurrent Hepatoblastoma2Recurrent Langerhans Cell Histiocytosis2Recurrent Malignant Germ Cell Tumor2Recurrent Malignant Solid Neoplasm2Recurrent Medulloblastoma2Recurrent Neuroblastoma2Recurrent Non-Hodgkin Lymphoma2Recurrent Osteosarcoma2Recurrent Peripheral Primitive Neuroectodermal Tumor2Recurrent Primary Central Nervous System Neoplasm2Recurrent Rhabdoid Tumor2Recurrent Soft Tissue Sarcoma2Refractory Langerhans Cell Histiocytosis2Refractory Malignant Germ Cell Tumor2Refractory Malignant Solid Neoplasm2Refractory Medulloblastoma2Refractory Neuroblastoma2

Trial status mix

ACTIVE_NOT_RECRUITING2
COMPLETED1
NO_LONGER_AVAILABLE1
RECRUITING1
TERMINATED1

Phase mix

PHASE24
PHASE13

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.